CN115243691A - Irak4抑制剂治疗ali/ards中的应用 - Google Patents
Irak4抑制剂治疗ali/ards中的应用 Download PDFInfo
- Publication number
- CN115243691A CN115243691A CN202180018110.9A CN202180018110A CN115243691A CN 115243691 A CN115243691 A CN 115243691A CN 202180018110 A CN202180018110 A CN 202180018110A CN 115243691 A CN115243691 A CN 115243691A
- Authority
- CN
- China
- Prior art keywords
- acute
- lung injury
- medicament
- respiratory distress
- distress syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
IRAK4小分子抑制剂在制备治疗或预防急性肺损伤或急性呼吸窘迫综合症及其相关病症的药物的应用。通过实验证明,所述IRAK4小分子抑制剂能够明显的减少炎症因子的产生,阻止嗜酸性粒细胞、中性粒细胞和淋巴细胞的浸润,对LPS诱导的急性肺损伤或急性呼吸窘迫综合症显示出良好的预防和治疗作用,有望成为新一代的治疗急性肺损伤和急性呼吸窘迫综合症的药物。
Description
PCT国内申请,说明书已公开。
Claims (10)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020103286487 | 2020-04-20 | ||
CN202010328648.7A CN113521079A (zh) | 2020-04-20 | 2020-04-20 | Irak4抑制剂在治疗ali/ards中的应用 |
PCT/CN2021/087924 WO2021213287A1 (zh) | 2020-04-20 | 2021-04-16 | Irak4抑制剂治疗ali/ards中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115243691A true CN115243691A (zh) | 2022-10-25 |
Family
ID=78124068
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010328648.7A Pending CN113521079A (zh) | 2020-04-20 | 2020-04-20 | Irak4抑制剂在治疗ali/ards中的应用 |
CN202180018110.9A Pending CN115243691A (zh) | 2020-04-20 | 2021-04-16 | Irak4抑制剂治疗ali/ards中的应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010328648.7A Pending CN113521079A (zh) | 2020-04-20 | 2020-04-20 | Irak4抑制剂在治疗ali/ards中的应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20230210833A1 (zh) |
CN (2) | CN113521079A (zh) |
WO (1) | WO2021213287A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024094190A1 (zh) * | 2022-11-04 | 2024-05-10 | 上海领泰生物医药科技有限公司 | Irak4降解剂及其用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
CN107406416A (zh) * | 2014-11-26 | 2017-11-28 | 拜耳医药股份有限公司 | 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
CN107872977A (zh) * | 2015-04-30 | 2018-04-03 | 拜耳制药股份公司 | Irak4抑制剂与btk抑制剂的组合产品 |
CN109071491A (zh) * | 2016-04-29 | 2018-12-21 | 拜耳医药股份有限公司 | 吲唑的合成 |
CN109152771A (zh) * | 2016-06-01 | 2019-01-04 | 拜耳医药股份有限公司 | 2-取代的吲唑用于治疗和预防自身免疫疾病的用途 |
CN109219603A (zh) * | 2016-06-01 | 2019-01-15 | 拜耳动物保健有限责任公司 | 用于治疗和预防动物的过敏性和/或炎症性疾病的取代吲唑 |
-
2020
- 2020-04-20 CN CN202010328648.7A patent/CN113521079A/zh active Pending
-
2021
- 2021-04-16 WO PCT/CN2021/087924 patent/WO2021213287A1/zh active Application Filing
- 2021-04-16 US US17/996,734 patent/US20230210833A1/en active Pending
- 2021-04-16 CN CN202180018110.9A patent/CN115243691A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107406416A (zh) * | 2014-11-26 | 2017-11-28 | 拜耳医药股份有限公司 | 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途 |
CN107872977A (zh) * | 2015-04-30 | 2018-04-03 | 拜耳制药股份公司 | Irak4抑制剂与btk抑制剂的组合产品 |
EP3219329A1 (en) * | 2016-03-17 | 2017-09-20 | Bayer Pharma Aktiengesellschaft | Combinations of copanlisib |
CN109071491A (zh) * | 2016-04-29 | 2018-12-21 | 拜耳医药股份有限公司 | 吲唑的合成 |
CN109152771A (zh) * | 2016-06-01 | 2019-01-04 | 拜耳医药股份有限公司 | 2-取代的吲唑用于治疗和预防自身免疫疾病的用途 |
CN109219603A (zh) * | 2016-06-01 | 2019-01-15 | 拜耳动物保健有限责任公司 | 用于治疗和预防动物的过敏性和/或炎症性疾病的取代吲唑 |
Also Published As
Publication number | Publication date |
---|---|
US20230210833A1 (en) | 2023-07-06 |
WO2021213287A1 (zh) | 2021-10-28 |
CN113521079A (zh) | 2021-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102364344B1 (ko) | 니코티닐 알콜 에테르 유도체, 그의 제조 방법, 및 그의 약학적 조성물 및 용도 | |
US10669252B2 (en) | Benzazepine derivative, preparation method, pharmaceutical composition and use thereof | |
CN101878221B (zh) | 糖皮质激素受体激动剂 | |
EP2890701B1 (en) | Kinase inhibitors | |
US11858945B2 (en) | Alkyne-containing antiviral agents | |
US11912714B2 (en) | Spiropyrrolidine derived antiviral agents | |
WO2022143845A1 (zh) | 含氮桥杂环化合物、其制备方法及其在医药上的应用 | |
EP3793995B1 (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
JP2024500286A (ja) | 新規スピロピロリジン誘導抗ウイルス剤 | |
JP2003516984A (ja) | ケモカインレセプターを結合する複素環式化合物 | |
CN115243691A (zh) | Irak4抑制剂治疗ali/ards中的应用 | |
US20230063462A1 (en) | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity | |
JP2020537658A (ja) | 呼吸器疾患治療のためのENaC阻害剤としてのビス(ペンタヒドロキシヘキシル)アミノ置換された2−{[(3−アミノ−ピラジン−2−イル)ホルムアミド]メチル}−1H−1,3−ベンゾジアゾール−3−イウム誘導体 | |
US20220265656A1 (en) | Combination therapies with ire1 small molecule inhibitors | |
CN115073447A (zh) | 小檗碱型吡啶甲酸类季铵盐化合物及其制备药物的用途 | |
CN115073446B (zh) | 小檗碱型生物碱氧化吡嗪甲酸季铵盐及其制备药物的用途 | |
CN113968861B (zh) | 具有PI3Kδ/BTK双靶点活性的化合物及其制备方法和应用 | |
WO2023169119A1 (zh) | 化合物的固体形式及其制备方法和用途 | |
US20240189289A1 (en) | Inhibitors of ephb3 signaling | |
US20230365525A1 (en) | Antiviral compounds | |
WO2023038815A1 (en) | Irak inhibitor for treating cytokine release-related conditions associated with infection by a respiratory virus | |
CN117357511A (zh) | Ginkgetin在制备STING抑制剂中的应用 | |
KR20220127825A (ko) | 화합물 및 α1-항트립신 결핍의 치료를 위한 이의 용도 | |
TW201022192A (en) | Tryptase enzyme inhibiting aminothiophenols | |
CN111343973A (zh) | 用于治疗一些肉瘤的il-8抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |